- Home
- PHUN vs PYXS Comparison
PHUN vs PYXS Comparison
Compare PHUN & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- PYXS
- Stock Information
- Founded
- PHUN 2009
- PYXS 2018
- Country
- PHUN United States
- PYXS United States
- Employees
- PHUN N/A
- PYXS N/A
- Industry
- PHUN EDP Services
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- PYXS Health Care
- Exchange
- PHUN Nasdaq
- PYXS Nasdaq
- Market Cap
- PHUN 64.1M
- PYXS 75.0M
- IPO Year
- PHUN N/A
- PYXS 2021
- Fundamental
- Price
- PHUN $3.11
- PYXS $1.16
- Analyst Decision
- PHUN Buy
- PYXS Strong Buy
- Analyst Count
- PHUN 2
- PYXS 5
- Target Price
- PHUN $7.75
- PYXS $9.00
- AVG Volume (30 Days)
- PHUN 269.3K
- PYXS 730.5K
- Earning Date
- PHUN 08-07-2025
- PYXS 08-13-2025
- Dividend Yield
- PHUN N/A
- PYXS N/A
- EPS Growth
- PHUN N/A
- PYXS N/A
- EPS
- PHUN N/A
- PYXS N/A
- Revenue
- PHUN $2,956,000.00
- PYXS N/A
- Revenue This Year
- PHUN $3.01
- PYXS N/A
- Revenue Next Year
- PHUN $50.72
- PYXS N/A
- P/E Ratio
- PHUN N/A
- PYXS N/A
- Revenue Growth
- PHUN N/A
- PYXS N/A
- 52 Week Low
- PHUN $2.22
- PYXS $0.83
- 52 Week High
- PHUN $14.60
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- PHUN 50.33
- PYXS 48.50
- Support Level
- PHUN $3.16
- PYXS $1.11
- Resistance Level
- PHUN $3.56
- PYXS $1.20
- Average True Range (ATR)
- PHUN 0.16
- PYXS 0.08
- MACD
- PHUN -0.01
- PYXS 0.00
- Stochastic Oscillator
- PHUN 42.62
- PYXS 42.86
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.